BetterLife Pharma Inc.

Equities

BETRF

CA08772P2026

Biotechnology & Medical Research

Delayed OTC Markets Other stock markets 09:41:15 2024-07-09 am EDT			5-day change	1st Jan Change
0.1242 ^USD	-6.07%		+38.46%	+158.75%

Jul. 02	BetterLife Pharma Inc. announced that it has received CAD 0.175 million in funding	CI
Jun. 27	BetterLife Pharma Inc. Reports Earnings Results for the First Quarter Ended April 30, 2024	CI

BetterLife Pharma Inc. Confirms Non-Controlled Status of 2-Bromo-LSD with Health Canada

January 19, 2021 at 02:19 pm EST

BetterLife Pharma Inc. announced that Health Canada has confirmed that 2-bromo-LSD is not a controlled substance. According to Health Canada, "the information currently available at the Controlled Substances Directorate, 2-bromo-LSD is NOT CONTROLLED under the Schedules to the Controlled Drugs and Substances Act.".

Latest news about BetterLife Pharma Inc.

BetterLife Pharma Inc. announced that it has received CAD 0.175 million in funding	Jul. 01	CI
BetterLife Pharma Inc. Reports Earnings Results for the First Quarter Ended April 30, 2024	Jun. 27	CI
BetterLife Pharma Raises $530,000 in Private Placement	Jun. 14	MT
BetterLife Pharma Inc. announced that it has received CAD 0.53 million in funding	Jun. 13	CI
BetterLife Pharma Inc. announced that it expects to receive CAD 0.175 million in funding	Jun. 12	CI
BetterLife Pharma Inc. Reports Earnings Results for the Full Year Ended January 31, 2024	May. 29	CI
BetterLife Obtains Excellent Animal Cardiopulmonary Safety Data for Oral BETR-001	May. 14	CI
BetterLife Pharma Inc. announced that it expects to receive CAD 0.5 million in funding	May. 02	CI
BetterLife Pharma Advances IND-enabling Studies For BETR-001	May. 01	MT
BetterLife Pharma Inc. Advances BETR-001 IND-Enabling Studies	May. 01	CI
BetterLife Pharma Inc. announced that it has received CAD 1.168 million in funding	Apr. 02	CI
BetterLife Pharma Inc. announced that it expects to receive CAD 0.1 million in funding	Mar. 03	CI
BetterLife Pharma Inc. announced that it has received CAD 0.065 million in funding	Mar. 03	CI
BetterLife Closes Convertible Debentures For Further Development of BETR-001	Jan. 02	MT
BetterLife Pharma Inc. announced that it has received CAD 0.3 million in funding	Jan. 01	CI
BetterLife Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended October 31, 2023	Dec. 29	CI
BetterLife Pharma Inc. announced that it has received CAD 0.2 million in funding	Dec. 17	CI
Us Patent and Trademark Office Publishes Betterlife?S Comprehensive Patent for Betr-001 and Other Lsd Derivatives	Nov. 30	CI
BetterLife Pharma Inc. Reports Earnings Results for the Second Quarter and Six Months Ended July 31, 2023	23-09-27	CI
BetterLife Pharma Inc. Obtains Favourable Animal Safety Data for Repeated Oral Dosing of BETR-001	23-09-12	CI
BetterLife Pharma Inc. announced that it has received CAD 0.295 million in funding	23-08-30	CI
BetterLife Pharma Inc. announced that it has received CAD 0.22 million in funding	23-07-12	CI
BetterLife Pharma Inc. Reports Earnings Results for the First Quarter Ended April 30, 2023	23-06-28	CI
BetterLife Pharma Inc. Fast Tracking Its US Patent for BETR-001 and Other LSD Derivatives	23-06-27	CI
BetterLife Pharma Inc. Announces Appointment of Steven Sangha as Corporate Development Advisor	23-06-22	CI

Chart BetterLife Pharma Inc.

Duration

Period

More charts

Company Profile

BetterLife Pharma Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing two compounds, BETR-001 and BETR-002, to treat neuro-psychiatric and neurological disorders. BETR-001 is a non-hallucinogenic Lysergic Acid Diethylamide (LSD) derivative. BETR-001 mimics the projected therapeutic properties of LSD without causing its undesirable side effects such as hallucinations and cardiac toxicity. BETR-001 is a therapy to treat debilitating psychiatric disorders with high unmet need, such as major depressive disorder and anxiety disorders; as well as neurological disorders such as neuropathic pain. BETR-002 is a formulation of a derivative of dihydrohonokiol, a known anti-anxiety compound for treatment of benzodiazepine dependency, anxiety and spasticity. The Company also owns a drug candidate for the treatment of viral infections such as COVID-19. The Companyâs subsidiaries include MedMelior Inc., BetterLife Pharma US Inc. and Blife Therapeutics Inc.

Sector

Biotechnology & Medical Research

Calendar

2024-09-24 - Q2 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
BETTERLIFE PHARMA INC.	+158.75%	16.18M
VERTEX PHARMACEUTICALS INCORPORATED	+19.35%	124B
REGENERON PHARMACEUTICALS, INC.	+20.13%	114B
ARGENX SE	+21.11%	25.83B
BIONTECH SE	-24.09%	19.42B
GENMAB A/S	-18.17%	16.2B
BEIGENE, LTD.	-19.58%	15.31B
SAREPTA THERAPEUTICS, INC.	+55.68%	14.32B
NEUROCRINE BIOSCIENCES, INC.	+5.83%	14.31B
WUXI APPTEC CO., LTD.	-48.79%	14.19B

Bio Therapeutic Drugs